newsfilter.io

George Church

Showing 1–3 of 3 transcripts.

  1. The Economist25 min

    Gene editing: should you be worried?

    James Dale, Isla Mirada, Natalie Kofler, Emmanuelle Charpentier, Jennifer Doudna, Josh Lehrer, Denis Rebrikov, Theresa Blankmeyer-Burke, He Zhongkui, George Church

    Recent advancements in CRISPR and gene editing have accelerated scientific capabilities for curing terminal diseases, securing food supplies against extinction events like the banana fungus TR4, and controlling disease vectors, yet these tools introduce significant ethical risks regarding bio-warfare, social inequality, and the potential for designer humans. While regulatory frameworks vary globally between the strict bans in Europe and the more permissive approaches in the US and Japan, controversies persist over transparency in field trials and the morality of germline editing, as highlighted by critiques from bioethicists regarding community consent and the normalization of de-extinction projects. Ultimately, experts warn that without robust, transparent governance to balance rapid innovation with safety, humanity risks undermining public trust while failing to leverage these essential technologies to mitigate climate change and ensure future food security.

  2. a16z41 min

    a16z Podcast | What's in the Water at the George Church Lab?

    George Church, Jorge Conde, Hannah

    George Church analyzes the 2018 Chinese CRISPR baby case as a pivotal, government-tolerated precedent for germline editing that bypassed ethical moratoriums through a technical strategy of *CCR5* knockout for HIV resistance. He predicts that, similar to the 1978 test-tube baby phenomenon, this "n of 1" success will accelerate adoption and regulation rather than halt research, shifting the field from treatment toward preventative genomic medicine. While Church advocates for robust privacy frameworks like zero-dollar genomes and encryption to overcome security barriers, his broader vision prioritizes environmental applications like mammoth de-extinction over non-therapeutic human editing.

  3. Milken Institute1h 7m

    Precision Medicine, Custom Cures

    Margaret Anderson, Mike Polini, Jim Greenwood, George Church, Retta Berry, Chris Austin

    Led by former NIH Director Francis Collins and moderated by Margaret Anderson, a diverse panel of scientists, industry leaders, and patient advocates examined the critical gap between rapid advances in precision medicine sequencing and clinical deployment. While the discussion highlighted success stories like the Berry family's transition from a diagnostic odyssey to effective treatment and the rising adoption of gene therapies, it also exposed systemic bottlenecks in rare disease therapeutics, reimbursement models, and data silos that prevent timely translation of genetic discoveries into cures. The group concluded that realizing the full potential of this medical revolution requires structural healthcare reform, robust data-sharing frameworks, and a shift toward participatory medicine where patients actively drive their own health outcomes.